Topsail Wealth Management LLC Reduces Holdings in Eli Lilly and Company $LLY

Topsail Wealth Management LLC lowered its stake in Eli Lilly and Company (NYSE:LLY) by 5.3% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 735 shares of the company’s stock after selling 41 shares during the period. Topsail Wealth Management LLC’s holdings in Eli Lilly and Company were worth $573,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of LLY. WestEnd Advisors LLC increased its position in shares of Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after purchasing an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC acquired a new position in shares of Eli Lilly and Company in the 1st quarter valued at about $27,000. Blume Capital Management Inc. boosted its holdings in shares of Eli Lilly and Company by 46.7% in the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after buying an additional 14 shares during the period. Citizens National Bank Trust Department boosted its holdings in shares of Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after buying an additional 27 shares during the period. Finally, IMG Wealth Management Inc. acquired a new position in shares of Eli Lilly and Company in the 2nd quarter valued at about $35,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.6%

Shares of NYSE:LLY opened at $825.86 on Friday. The company has a 50 day moving average of $768.01 and a 200-day moving average of $768.44. The firm has a market cap of $781.65 billion, a P/E ratio of 53.98, a P/E/G ratio of 1.19 and a beta of 0.47. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $935.63. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business’s revenue for the quarter was up 37.6% compared to the same quarter last year. During the same period in the prior year, the business posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Eli Lilly and Company news, CEO David A. Ricks bought 1,632 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Daniel Skovronsky bought 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the acquisition, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. This represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 4,514 shares of company stock worth $2,894,841. Company insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the subject of several research reports. Leerink Partners reaffirmed a “market perform” rating and issued a $715.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 7th. DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a report on Monday, August 11th. HSBC lifted their price target on shares of Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $938.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.